title: Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas.
abstract: OBJECTIVE
  The effects of neoadjuvant chemotherapy (CT) on Ki-67 and proliferating cell nuclear antigen (PCNA) labeling index (LI) were analyzed, using biopsy and surgical specimens of esophageal cancer.
  
  
  METHODS
  Immunohistochemical staining for Ki-67 and PCNA was performed for biopsy and surgical specimens of 35 patients with esophageal squamous cell carcinoma. Seventeen patients were treated with neoadjuvant CT (CT group), while no preoperative treatment was performed for the remaining 18 patients (control group). As neoadjuvant CT, cisplatin of 50 mg/body/week was administered 2-5 times (100-250 mg in total) until 7-10 days before subtotal esophagectomy.
  
  
  RESULTS
  Significant correlation between the LIs of biopsy and surgical specimens was observed for the control group (p = 0.006 for Ki-67 and p = 0.005 for PCNA), although both LIs of surgical specimens were significantly higher than those of biopsy specimens (p < 0.05). However, no significant correlation between LIs of biopsy specimens and those of surgical specimens was observed for the CT group. In addition, the LIs of the surgical specimens of the CT group were significantly lower than the LIs of the control group (p < 0.005 for Ki-67 and p < 0.05 for PCNA). Significant decrease in Ki-67 LI after neoadjuvant CT was noted especially for well or moderately differentiated squamous cell carcinomas and/or tumors treated with high-dose cisplatin (150-250 mg).
  
  
  CONCLUSIONS
  Significant correlation of Ki-67 and PCNA LIs between biopsy and surgical specimens was demonstrated for the control group. Neoadjuvant CT decreased the percentage of cycling and proliferative tumor cells of esophageal cancer.
authors.affiliation: Department of Therapeutic Radiology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Horii
authors.forename: Y
authors.initials: Y
authors.lastname: Nishimura
authors.forename: Y
authors.initials: Y
authors.lastname: Okuno
authors.forename: S
authors.initials: S
authors.lastname: Kanamori
authors.forename: M
authors.initials: M
authors.lastname: Hiraoka
authors.forename: Y
authors.initials: Y
authors.lastname: Shimada
authors.forename: M
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000188:drug therapy / Q000601:surgery; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000601:surgery; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen